Pharmacokinetic Profile and Safety of Fluticasone Propionate and Albuterol Sulfate in Combination When Compared to Fluticasone Propionate Multidose Dry Powder Inhaler (Fp MDPI) in Children Aged 4 to 11 Years Old
Public ClinicalTrials.gov record NCT06290102. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open Label, Single Dose, 3-Period, Crossover Study to Determine the Pharmacokinetic Profile and Safety of Fluticasone Propionate/Albuterol Sulfate (Fp/ABS) Multidose Dry Powder Inhaler With e-Module (eMDPI) Compared to Fluticasone Propionate Multidose Dry Powder Inhaler (Fp MDPI) in Participants With Asthma (4 to 11 Years Old)
Study identification
- NCT ID
- NCT06290102
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Industry
- Enrollment
- 30 participants
Conditions and interventions
Conditions
Interventions
- TEV-56248 Drug
- Fp MDPI Drug
Drug
Eligibility (public fields only)
- Age range
- 4 Years to 11 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 15, 2024
- Primary completion
- Sep 30, 2024
- Completion
- Oct 6, 2024
- Last update posted
- Aug 13, 2025
2024
United States locations
- U.S. sites
- 10
- U.S. states
- 7
- U.S. cities
- 8
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Teva Investigational Site 12010 | Mobile | Alabama | 36608 | — |
| Teva Investigational Site 12003 | Long Beach | California | 90815 | — |
| Teva Investigational Site 12007 | Miami | Florida | 33130 | — |
| Teva Investigational Site 12005 | Miami | Florida | 33142 | — |
| Teva Investigational Site 12002 | Miami | Florida | 33155 | — |
| Teva Investigational Site 12008 | Lafayette | Louisiana | 70508 | — |
| Teva Investigational Site 12011 | Columbia | Missouri | 65203 | — |
| Teva Investigational Site 12012 | Oklahoma City | Oklahoma | 73120-9389 | — |
| Teva Investigational Site 12001 | Boerne | Texas | 78006 | — |
| Teva Investigational Site 12009 | San Antonio | Texas | 78249 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06290102, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 13, 2025 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06290102 live on ClinicalTrials.gov.